Atenolol

Quick links to important sections

Atenolol

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atenolol

Atenolol: Quick Facts

Property Description
Active ingredient Atenolol
Form Tablet, Intravenous (IV) solution
Pharmacological class Beta-blocker (β-blocker)
Specific classification Selective β1-adrenergic receptor antagonist
Origin Synthetic compound

What Type of Medication is Atenolol?

Atenolol is a synthetic prescription drug classified as a beta-blocker (β-blocker), a pharmaceutical class used for its effects on cardiovascular regulation. It is a beta-1 selective (cardioselective) adrenergic receptor blocking agent. This selectivity is a major differentiating factor, as it means the drug primarily targets the β1-receptors found predominantly in the heart, minimizing interaction with β2-receptors elsewhere. This characteristic focus on the heart is associated with supporting stable cardiac function.

Composition, Origin, and Available Forms

The therapeutic effect is derived from the single active ingredient, Atenolol, a substance produced entirely through chemical synthesis. Chemically, it is described by its IUPAC-derived name, 4-[2'-hydroxy-3'-[(1-methylethyl)amino]propoxy]benzeneacetamide. The medicine is manufactured for oral intake in the form of a tablet and, for urgent or hospital-based needs, as an intravenous solution. Its nature as a highly polar, hydrophilic compound with low lipid solubility is a differentiating chemical feature that limits its ability to penetrate the central nervous system compared to more lipophilic β-blockers.

General Purpose: Reducing Workload on the Heart

The general purpose of this medication is to support the cardiovascular system by reducing the overall workload and oxygen demand of the heart muscle. This action is utilized in scenarios where the heart is subjected to strain, such as managing a consistently rapid or forceful heartbeat. By acting as a β1-antagonist, it achieves a sympatholytic effect, which decreases the heart rate and lessens the force of myocardial contraction. The overall role is to foster efficient cardiac performance.

Regulatory References

  1. Atenolol - StatPearls - NCBI Bookshelf

What side effects are possible with Atenolol?

Atenolol’s safety profile, as documented in official government sources, involves side effects classified by the body systems they affect, and important restrictions on use.

Adverse Reactions and Side Effects

Adverse reactions are categorized by frequency, including Common effects such as fatigue, cold extremities, a slow heart rate (bradycardia), and gastrointestinal disturbances. Rare adverse reactions documented include dizziness, headache, sleep disturbances, confusion, visual and eye disorders (e.g., dry eyes), bronchospasm, hair loss (alopecia), and worsening of existing psoriasis or psoriasiform rash.

Critical Safety Warnings and Restrictions

Abrupt Withdrawal Risk

The medicine should not be suddenly discontinued, especially in patients with ischemic heart disease. Rapid withdrawal has been associated with a risk of worsening chest pain (angina pectoris), myocardial infarction (heart attack), and severe irregular heartbeats (ventricular arrhythmias).

Contraindications (Situations Prohibiting Use)

Atenolol is officially contraindicated in patients with certain severe pre-existing heart conditions, including slow heart rate (sinus bradycardia), certain types of heart block (second or third degree), cardiogenic shock, or overt heart failure. It is also restricted in cases of untreated adrenal gland tumor (pheochromocytoma) and in patients with metabolic acidosis.

Population-Specific Considerations

  • Kidney Impairment: Because Atenolol is eliminated primarily by the kidneys, patients with reduced kidney function (renal impairment) require specific dose adjustment based on creatinine clearance.
  • Pregnancy and Breastfeeding: Use during pregnancy is not recommended due to potential risks to the developing fetus, such as growth restriction. The medicine is excreted into breast milk, and caution is advised in breastfeeding mothers, especially with newborns or premature infants.
  • Diabetics: The medicine may mask key warning signs of low blood sugar (hypoglycemia), such as a fast heartbeat, requiring careful monitoring in patients with diabetes.

Overdose and Emergency Response

Overdose and when to Seek Help — Official Regulatory Information for Atenolol

Attribute Official Regulatory Statement
Documented Overdose Presentations Profound bradycardia (slow heart rate), severe hypotension (low blood pressure), onset of congestive heart failure, bronchospasm, marked lethargy, and hypoglycemia (low blood sugar).
Life-Threatening Outcomes Overdosage may lead to cardiogenic shock, cardiac arrest, and coma.
Emergency Actions Mandated Call an emergency number or the Poison Control Hotline immediately. Medical personnel may employ gastric lavage, activated charcoal, and hemodialysis for drug removal.
When Immediate Medical Help is Required Seek medical help right away. Immediate medical attention is required if the victim has collapsed, had a seizure, is experiencing trouble breathing, or can't be awakened.
Population-Specific Notes Hypoglycemia is common in children following overdose. Patients with renal impairment are at increased risk of toxicity due to impaired elimination.

Resulting Overdose Structure

Official regulatory labeling defines the Atenolol overdose profile by documenting expected severe cardiodepression and related systemic complications. Monitoring of vital signs and an ECG is required in management settings. There is no specific antidote listed in the primary prescribing information; therefore, management focuses on supportive care to counter the documented clinical effects. These severe risks, including the potential for cardiac arrest and coma, require the user to seek medical help right away upon recognizing these acute manifestations.

Therapeutic Uses of Atenolol

What Atenolol Treats: Main Uses and Benefits

Atenolol is commonly used across conditions presenting with systemic or localized discomfort related to the cardiovascular system. The medication is used for the long-term management of hypertension (high blood pressure). This treatment addresses the underlying strain on the systemic circulation, which may assist with reducing the potential for severe cardiovascular events, such as stroke and heart attack.

Key Therapeutic Applications

The medication is commonly used across conditions characterized by periods of heightened symptoms related to elevated blood pressure, recurring chest discomfort (angina), and rapid heart rhythms (tachycardia). The medication is applied in addressing conditions such as hypertension, chronic stable angina pectoris, and supportive care following an acute myocardial infarction. It is also relevant for easing pronounced physical symptoms, such as tremor and rapid pulse, in conditions marked by increased physiological stress, including thyrotoxicosis or acute alcohol withdrawal.

“This medicine is commonly used to help with symptom clusters that may become intense, supporting the patient during difficult symptomatic periods.”

This application helps maintain a sense of stability and supports general well-being during symptomatic phases by easing the overall symptom load.


Quick Fact

Quick Fact: Relief for Symptoms of Cardiac Overactivity Description
Primary Symptoms Elevated blood pressure, recurring chest pain, rapid/irregular heart rhythms (palpitations).
Benefit Focus Provides support that helps ease the overall symptom burden by moderating the heart’s activity.
Context of Use Used for long-term chronic management and supportive care in acute cardiac settings.

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Who Can and Cannot Use Atenolol?

Eligibility for Atenolol use is strictly defined by regulatory authorities and centers on the patient's existing health status, particularly cardiac function and kidney health. The medication is approved for use in the Adult Population for its labeled indications (e.g., hypertension and angina).


Absolute Contraindications

Regulatory labeling states that Atenolol must not be used in patients with:

  • Sinus Bradycardia or Heart Block greater than first degree.
  • Overt or Uncontrolled Cardiac Failure or Cardiogenic Shock.
  • Severe Peripheral Arterial Circulatory Disturbances, Hypotension, or Metabolic Acidosis.

Conditional and Restricted Use

  • Renal Impairment: The dose must be reduced when creatinine clearance is below 35 mL/min due to slower elimination.
  • Pediatric Population: Use is not recommended as safety and efficacy have not been established.
  • Pregnancy and Lactation: Use is restricted and generally advised only if the benefit outweighs the potential risk. Atenolol is excreted into human milk, necessitating caution.
  • Bronchospastic Diseases (e.g., Asthma): Use is generally not recommended, but may be used with caution if alternatives are not suitable.

Regulatory documents use these defined health constraints to distinguish eligible adult populations from those who are non-eligible or require conditional use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Atenolol’s interaction profile is primarily defined by pharmacodynamic reinforcement and its dependence on renal clearance for elimination. Regulatory bodies formally document interactions with specific medication classes and products that may alter its effects or exposure in the body.

Documented Interaction Patterns

Interaction Type Interacting Substances/Class Official Interaction Pattern
Cardiovascular Pharmacodynamics Verapamil, Diltiazem, Digoxin Additive negative chronotropic (heart rate slowing) and inotropic (contractility reducing) effects, increasing risk of bradycardia and heart block.
Antihypertensive Efficacy Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May antagonize the intended blood pressure-lowering effect of Atenolol.
Absorption/Exposure Calcium Salts, Orange Juice Reduces oral bioavailability, lowering peak plasma concentration (Cmax) and overall exposure (AUC).
Pharmacodynamic Risk Management Clonidine Abrupt withdrawal of Clonidine while co-administering Atenolol is associated with a risk of severe hypertensive rebound.

Administration Constraints and Considerations

The regulatory profile mandates specific timing rules: co-administration with oral Calcium Salts requires the doses to be separated by at least two hours to mitigate reduced absorption. Since Atenolol is predominantly removed from the body via the kidneys, official warnings note that individuals with impaired renal function are at a higher risk of drug accumulation and enhanced systemic exposure. The combination of Atenolol with other beta-blockers is not advised due to the potential for excessive cardio-depressant effects.

Mechanism of Action

Atenolol is a beta1-selective adrenergic receptor antagonist primarily targeting receptors located on cardiac tissue. Its molecular interaction involves competitive binding to the beta1-adrenergic receptor, preventing the endogenous agonists, epinephrine and norepinephrine, from activating the receptor.

At the intracellular level, this competitive antagonism inhibits the Gs protein-coupled pathway. Specifically, it blocks the agonist-mediated increase in adenylyl cyclase activity, thereby reducing the intracellular concentration of cyclic adenosine monophosphate (cAMP). The decreased cAMP concentration subsequently reduces the activity of Protein Kinase A (PKA).

This reduction in PKA-mediated phosphorylation leads to several effects within myocardial cells, including decreased calcium influx through L-type calcium channels and reduced phosphorylation of phospholamban. The overall effect on the heart is a reduction in chronotropy (heart rate) and inotropy (contractility). The system-level physiological consequence is a decrease in cardiac output and the modulation of oxygen consumption by the myocardium.

Dosage and Administration Information

Official Administration Routes and Dosing Protocols

Atenolol is administered via two official routes: the oral route (tablet) for chronic, long-term maintenance, and the intravenous (IV) route (solution) for initial intervention in specific acute conditions.

Standard Labeled Dosing Regimens (Adult)

Indication (High-Level) Starting Oral Dose Maintenance Oral Range Max Dose Limit
Hypertension 50 mg once daily 50 mg to 100 mg once daily 100 mg daily
Angina Pectoris 50 mg once daily 100 mg once daily 200 mg daily

Oral tablets are typically taken once daily, a frequency pattern based on the observation that the anti-hypertensive effect persists for at least 24 hours following doses of 50 mg or 100 mg. The full effect of a starting oral dose is typically evaluated after one to two weeks before any dosage adjustment is considered.


Contextual and Population-Specific Administration

Procedural Element Official Guideline
Timing in Relation to Meals Tablets may be taken without regard to meals and should be swallowed whole with water.
Renal Impairment Dose must be reduced: Maximum oral dose is 50 mg daily for Creatinine Clearance 15–35 mL/min/1.73 m^2.
Hemodialysis 25 mg or 50 mg is administered orally after each dialysis session.
Discontinuation Rule After long-term use, abrupt cessation is prohibited; the dose must be gradually tapered over a period of 7 to 14 days.

For Acute Myocardial Infarction, the protocol involves a phased sequence: an IV injection is followed by oral 50 mg doses 10 minutes and 12 hours later, transitioning to the maintenance dose for 6 to 9 days or until hospital discharge. In the case of a missed dose, the instruction is to skip the missed dose and resume the regular schedule; double doses must not be taken. Use in children is generally not recommended due to limited established experience.

Recent Clinical Evidence

Atenolol: Recent Clinical Evidence

This overview summarizes the available research and clinical trial evidence for Atenolol, based on regulatory filings and peer-reviewed scientific literature. This information is intended to describe the existing body of evidence and is not clinical advice.


Evidence for Use in the Study of High Blood Pressure (Hypertension)

Research for Atenolol in the study of high blood pressure has primarily involved Randomized Controlled Trials (RCTs) and large-scale Systematic Reviews and Meta-analyses. These studies were used in research exploring symptom measurements over defined time intervals. The outcomes monitored included measurements of both Systolic and Diastolic Blood Pressure and the assessment of major composite cardiovascular events. Findings were mixed across systematic reviews when they explored long-term protection against major events like stroke or heart attack, particularly when comparing the drug to some newer medication classes. Long-term clinical outcomes on cardiovascular events are not fully established in all contemporary comparative settings.


Evidence for Use in the Study of Chronic Stable Chest Discomfort (Angina Pectoris)

Evidence related to Atenolol for chronic stable chest discomfort, known as angina pectoris, was primarily derived from short-term and intermediate-term Randomized Controlled Trials. These studies explored outcomes related to physical discomfort, specifically the frequency and perceived intensity of chest pain episodes. Research so far describes patterns observed in the long-term observational settings related to symptom measurements. Limited large-scale modern RCTs specifically compare Atenolol against the full range of currently available anti-anginal drugs.


Evidence in Supportive Care Following a Heart Attack (Post-Myocardial Infarction)

Atenolol was studied for use in supportive care following an acute myocardial infarction. The evidence base includes early Randomized Controlled Trials, supported by large Individual Patient Data Meta-analyses. The findings describe patterns observed in the studies related to all-cause mortality and the risk of recurrent myocardial infarction in the post-event phase. The certainty for long-term clinical outcomes in all patient subgroups remains low, especially in patients who maintain a preserved cardiac function following modern acute care protocols. Data for this group are still emerging.

Key Studies & References

  1. DailyMed Label: Atenolol Tablet (NIH NLM)
  2. MedlinePlus Drug Information: Atenolol (NIH NLM)
  3. NIH StatPearls: Atenolol (Review covering pharmacology and lipophilicity)

Frequently Asked Questions (FAQ)

Common questions about Atenolol (FAQ)


Q: How quickly does the effect of a single Atenolol dose start to wear off?

The time it takes for a single dose of Atenolol to be processed by the body is measured by its elimination half-life. For the oral tablet, regulatory information indicates this half-life is approximately 6 to 7 hours. This is the time needed for the concentration of the medication in the bloodstream to decrease by half.


Q: Is it better to take Atenolol in the morning or at night?

Official product information states that Atenolol tablets are typically taken once daily, ideally at the same time each day. Although the drug can be taken at any time, some sources suggest taking the first dose at bedtime. This timing consideration may be related to the potential for effects such as temporary dizziness after the initial dose.


Q: Does Atenolol affect my ability to drive or operate machinery?

Caution is advised regarding driving or operating machinery while taking Atenolol. Official information indicates that side effects such as dizziness or tiredness are possible. Individuals are generally advised to exercise caution with these activities until they are aware of how the medication affects them, particularly regarding these potential symptoms.


Q: What kind of regular monitoring (e.g., blood pressure checks) is needed while on Atenolol?

Official warnings and precautions emphasize the necessity of regular monitoring, which typically includes checking blood pressure and heart rate. Additionally, for patients with impaired renal (kidney) function, monitoring of kidney health is often necessary due to the medication’s clearance route from the body.


Q: Is it normal to have vivid dreams or nightmares when taking Atenolol?

Sleep disturbances, including vivid dreams or nightmares, are listed as a rare adverse reaction in regulatory documentation. While not common, official reports confirm that this side effect can occur in some individuals taking the medication.


Q: What should I do if I occasionally miss a dose of Atenolol?

Official instructions typically advise that if a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the instruction is to skip the missed dose and resume the regular schedule. It is officially mandated that a double dose must not be taken to compensate for a missed dose.


Q: What research supports the use of Atenolol for improving survival after a heart attack?

Clinical trial data, such as that used for regulatory approval, explored the drug's effect on factors like all-cause mortality and the risk of recurrent myocardial infarction in the phase following an acute heart attack. This research contributes to the drug’s use in supportive care post-myocardial infarction.


Q: Is it possible for Atenolol's effectiveness to decrease over time?

Regulatory information and clinical pharmacology data indicate that long-term studies have generally not shown any diminution of Atenolol's blood pressure-lowering effectiveness with prolonged use. This suggests the anti-hypertensive effect is generally expected to be maintained over the long term.


Q: Does Atenolol have any effect on thyroid conditions?

Official warnings and precautions note that Atenolol may mask the physical signs of thyrotoxicosis (severe overactive thyroid). This effect is noted by regulatory bodies as a factor to consider for individuals with pre-existing thyroid conditions.


Q: What kind of studies have been done on Atenolol's effectiveness in children?

Regulatory documentation clearly states that the safety and efficacy of Atenolol have not been established in the pediatric age group. Therefore, the medication is generally not recommended for use in children due to the limited established clinical experience in this population.


Q: Is Atenolol a long-term treatment, or is it possible to eventually stop taking it?

Atenolol is often prescribed for the long-term management of chronic conditions like hypertension and angina. If treatment discontinuation is necessary, official warnings state that the medication should not be stopped suddenly. Instead, the dose must be gradually reduced over a period of 7 to 14 days.


Q: How is Atenolol use approached in elderly patients?

Official regulatory information advises that dose selection for an elderly patient should be conducted with caution. This is generally related to the increased frequency of decreased kidney or liver function in older individuals, often necessitating cautious dose selection.


Q: What is the risk of Atenolol causing a drop in blood pressure when standing up (orthostatic hypotension)?

A drop in blood pressure upon standing, which is termed postural hypotension or orthostatic hypotension, is a documented adverse effect of Atenolol. Regulatory information reports that this effect was observed in a small percentage (2–4%) of patients in some clinical trials.


Q: Can Atenolol affect the results of a stress test or other heart function tests?

The mechanism of Atenolol is to reduce heart rate and cardiac workload. Since these are primary factors assessed during a stress test, the medication's pharmacological action can influence the test results. Due to this, the prescribing healthcare professional is aware that the test outcomes may require specific interpretation.


Q: Does Atenolol interact with any medications for an irregular heart rhythm?

Yes, official regulatory documents specifically detail interactions between Atenolol and certain medications used to treat irregular heart rhythms. For example, drugs like Digoxin are known to interact, which can result in excessive or additive heart rate slowing effects.

How should Atenolol be stored and disposed of?

Storage and Disposal: Official Regulatory Information

Atenolol tablets must be stored under Controlled Room Temperature conditions, which is defined as 20 C to 25 C (68 F to 77 F), with permitted short-term temperature excursions up to 30 C (86 F). The medication must not be stored above 25 C for some preparations.


Storage Requirements

Requirement Official Instruction
Temperature Store at 20 C to 25 C
Protection Keep in a tight, light-resistant container
Child Safety Must be kept out of the reach of children

Disposal Instructions

Regulatory guidance states that outdated or unused Atenolol must not be kept. Patients are instructed to consult a pharmacist or healthcare professional for specific guidance on how to properly dispose of any unused medicine. For some preparations, no special requirements for disposal are specified in the product documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atenolol found in:

A-Z Index: